Money and distorted ethical judgments about research: Ethical assessment of the TeGenero TGN1412 trial

American Journal of Bioethics

Volumn 7, Issue 2, 2007, Pages 76-81

  Emanuel, Ezekiel J ^a   Miller, Franklin G ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TGN1412; UNCLASSIFIED DRUG;

ANIMAL; CLINICAL TRIAL; ECONOMICS; ETHICS; HUMAN; INFORMED CONSENT; PATIENT SELECTION; REVIEW; RISK ASSESSMENT;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; HUMANS; INFORMED CONSENT; PATIENT SELECTION; RISK ASSESSMENT;

EID: 33847634741     PISSN: 15265161     EISSN: 15360075     Source Type: Journal    
DOI: 10.1080/15265160601111800     Document Type: Review

References (30)

1. Associated Press. 2006. Two men remain in coma after drug trial. March 21, 2006. Available at http://www.nytimes.com/aponline/international/AP-Britain- Trial.html (accessed on March 21, 2006).
2. Beecher, H.K. 1966. Ethics and clinical research. New England Journal of Medicine 274: 1354-1360.
3. Berg, J.W., P.S. Appelbaum, C.W. Lidz, and L.S. Parker. 2001. Informed consent: legal theory and clinical practice 2nd edition. New York, NY: Oxford University Press.
4. Bloomberg. 2006. Parexel misled subjects sickened in London study, ethicists say. April 10. Available at http://www.bloomberg.com/apps/news?pid= 20601186&sid=aG3sg1rIkL4U&refer=special_report (accessed on November 23, 2006).
5. Caplan, A. 2006. Risky business: Human testing for a profit. Available at http://www.msnbc.com/id/11927387/ (accessed on March 21, 2006).
6. Drazen, J.F. 2006. Volunteers at risk. New England Journal of Medicine 355(10): 1060-1061.
7. Emanuel, E.J. 2004. Ending concerns about undue inducement. Journal of Law, Medicine & Ethics 32: 100-105.
8. Emanuel, E.J., X.E. Currie, and A. Herman. 2005. Undue inducement in clinical research in developing countries: Is it a worry? Lancet 366: 336-340.
9. Emanuel, E.J., D. Wendler, and C. Grady. 2000. What makes clinical research ethical? Journal of the American Medical Association 283: 2701-2711.
10. Expert Scientific Group on Phase One Clinical Trials. 2006. Interim Report July 20, 2006. Available at http://www.dh.gov.uk/ Consultations/ LiveConsultations/LiveConsultationsArticle/fs/en?CONTENT_ID=4137501&chk= x%2BoJ/%2B (accessed on August 8, 2006).
11. Goodyear, M. 2006. Learning from the TGN1412 trial. British Medical Journal 332: 677-678.
12. Hawkins, J., and E.J. Emanuel. 2005. Clarifying confusions about coercion. Hastings Center Report 35(5): 16-19.
13. Horton, R. 1994. The context of consent. Lancet 344:211-212.
14. Informed Consent Form. 2006. Parexel Project Number 68419, Feb. 9, 2006. Available at http://www.circare.org/foia5/tgn1412_consentform.pdf (accessed on November 23, 2006).
15. Institute of Medicine. 1995. Review of the fialuridine (FIAU) clinical trials. Washington, DC: National Academy Press.
16. Laurance, J. 2006. Watchdog 'was given warning on danger of drug trial.' The Independent April 8, 2006. Available at http://news.independent.co. uk/uk/health_medical/article356455. ece (accessed on April 9, 2006).
17. Lutfullin, A., J. Kuhlmann, and G. Wensing G. 2005. Adverse events in volunteers participating in phase I clinical trials: A single center five-year survey in 1,559 subjects. International Journal of Clinical Pharmacology and Therapy 43: 217-26.
18. Medicines and Healthcare Products Regulatory Agency. 2006a. Clinical trial assessment report pharmaceutical data. Available at http://www.circare. org/foia5/tgn1412assessment-report.pdf
19. Medicines and Healthcare Products Regulatory Agency. 2006b. Investigations into adverse incidents during clinical trials of TGN1412: Interim report. Available at http://www.circare.org/foia5/ clinicaltrialsuspension_interimreport.pdf
20. Panja, T. 2006. Update 2: Illnesses raise drug-safety questions. Associated Press March 21, 2006. Available at http://www.forbes.com/ business/feeds/ap/2006/03/21/ap2611134.html (accessed on March 22, 2006.
21. Parexel. 2006. Clinical Trial Protocol, A phase-1, single-centre, double-blind, randomized, placebo-controlled, single escalating-dose study to assess the safety, pharmacokinetics, pharmacodynamics and immunogenicity of TGN1412 administered intravenously to healthy volunteers. Available at http://www.circare.org/foia5/tgn1412protocol.pdf
22. Reuters. 2006. Protein differences may explain drug reaction. March 19, 2006. Available online at http://www.nytimes.com/reuters/news/news-britain- trial-expert.html (accessed on March 20, 2006).
23. Schneider, C.K., U. Kalinke, and J. Lower. 2006. TGN 1412-a regulator's perspective. Nature Biotechnology 24: 493-496.
24. Sibille, M.,N. Deigat, A. Janin, S. Kirkesseli, and D.V. Durand. 1986. Adverse events in Phase I studies: a report in 1015 healthy volunteers. European Journal of Clinical Pharmacology 20: 243-257.
25. Stolberg, S.G. 1999. The biotech death of Jesse Gelsinger. New York Times Magazine November 29:137.
26. Suntharalingam, G., M.R. Perry, S. Ward, S.J. Brett, A. Castello-Cortes, M.D. Brunner, and N. Panoskaltsis. 2006. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN 1412. New England Journal of Medicine 355(10): 1018-1028.
27. Thompson, D. 1993. Understanding financial conflicts of interest. New England Journal of Medicine 329:573-576.
28. Waldman, M. 2006. London's disastrous drug trial has serious side effects for research. Nature 440:383.
29. Wendler, D., L. Belsky, K.M. Thompson, and E.J. Emanuel. 2005. Quantifying the federal minimal risk standard. Journal of the American Medical Association 294: 836-832.
30. Wertheimer, A. 1987. Coercion. Princeton, NJ: Princeton University Press.